Ninlaro

Generic Name/API: Ixazomib
Manufacturer: Takeda Pharmaceuticals U.S.A., Inc.
Packaging: Capsule form
Storage: Below 30°C
Dosage: 1.8 mg/kg; Intravenous
Strength: 2.3 mg/ 3 mg/ 4mg
Indication: Ixazomib or NINLARO is prescribed for multiple myeloma patients who have received at least one previous therapy.
No Indian generic option is available.
 
?>

About Ixazomib or Ninlaro 

Ixazomib is a proteasome inhibitor including a combination of lenalidomide and dexamethasone that is prescribed for multiple myeloma patients who have received at least one previous therapy.


Strength: Ninlaro is available in various strengths including 2.3 mg of Ixazomib equivalent to 3.3 mg of Ixazomib citrate, 3 mg of Ixazomib equivalent to 4.3 mg of Ixazomib citrate, and 4 mg of Ixazomib equivalent to 5.7 mg of Ixazomib citrate. 


Recommended Dosage

The initial recommended dosage is 4 mg orally in a week on Days 1, 8, and 15 following the 28-day cycle. The dosage must be revised and reduced to 3 mg or below in cases of reduced kidney and liver function. 

Important: In case of any severe effects from the medication, please consult your treating doctor. 


Warning & Precautions

  • During treatment, check platelet counts at least once a month, revise the dosage as necessary.
  • If you experience severe diarrhea, constipation, nausea, or vomiting, you should consult your doctor for changes in dosage. 
  • Observe patients for signs of peripheral neuropathy and change the dosage if necessary.
  • Take note of any fluid retention. Investigate potential underlying causes and change the dosage as and when necessary. 

Common side effects of Ixazomib

  • Diarrhea
  • Constipation
  • Thrombocytopenia
  • Peripheral neuropathy
  • Nausea
  • Peripheral edema
  • Vomiting
  • Back pain

Use in Specific Population

It is necessary to reduce the dosage of Ixazomib in cases of moderate to severe hepatic impairment. Reduce the dose to 3 mg in individuals with severe renal impairment or end-stage renal disease who require dialysis.

For the medicine procurement, we follow a simple four-step process. 

  1. Enquiry about the medicine: You make a request for information on the medicine you need, and we process your data. Within 24 hours, our Named Access Program Support team will contact you and offer you the necessary assistance.
  2. Verification Process: As we assist patients in finding medications that are not yet approved and readily available in their home countries, Sansfro must confirm the availability and approval of the medicines they need. We also check the patient’s prescription and medical information. 
  3. Sourcing the Medicine: After completing the verification process, our team will connect with our (network of suppliers) to find your medicine. Following the process, our team gets the best quote of the medicines for you and ensures processing. 
  4. Safe Delivery: We will set up the consignment’s safe delivery after the final quote is approved. Additionally, our logistics experts can help you track your consignment. The Named Access Program industry has a large number of unauthorized channels. To provide the medications safely and legally, we do so by adhering to the Standard Operating Procedures.

When importing medication, we will need the following documents from the patient:

  1. A valid prescription copy.
  2. An identity proof document.
  3. Details of the attending healthcare professional.
  4. A current address.

Once we have all these documents, the Sansfro team will initiate the application process for an import license. This license is essential to ensure that we can obtain the necessary medication once it receives government approval.

No news found.

About Sansfro

Sansfro is committed to bridging the healthcare gap. Our purpose is to bring hope and healing to patients suffering from rare diseases by linking them with life-saving treatments through our Named Patient Program. Join us in our quest for a better and healthier world.

Know More...

FAQ'S

How does NINLARO work?

NINLARO is a proteasome inhibitor that acts by inhibiting enzymes within cells, slowing cancer cell proliferation.

How is NINLARO taken?

NINLARO is taken orally as a capsule once a week, according to your doctor’s recommendation, or on Days 1, 8, and 15 following the 28-day cycle. The dosage must be revised by the doctor and reduced to 3 mg or below in cases of reduced kidney and liver function. 

What are the potential side effects of NINLARO?

Nausea, diarrhea, exhaustion, vomiting, low blood platelet levels, and peripheral neuropathy (numbness or tingling in the hands and feet) are common adverse effects of NINLARO or Ixazomib.

Please note that Ixazomib is the Active Pharmaceutical Ingredient of the product Ninlaro. 

How should I manage the side effects of NINLARO?

It is critical to discuss any adverse effects you have with your doctor. They can advise you on how to manage side effects and, if required, change your treatment plan.

Can I take NINLARO while pregnant or breastfeeding?

Since NINLARO has the potential to harm an unborn baby, it is typically not recommended during pregnancy. It is also recommended that you should not breastfeed while using NINLARO.

What is the price of NINLARO in India?

NINLARO price in India depends on the product requirement and the country where the product is ordered. Request more details by reaching out to our Patient Support Team at ‎(+91) 9315705373 or help@sansfro.com 

Dr Anchal Aryan

Medical counselor

Patient Support Head Detail

Dr Anchal Aryan

Medical counselor

COTACT US NOW

Patient Stories

Great Customer support
Invimeds Health boasts an exceptional team that consistently provides excellent customer service. We extend our gratitude to Sachin.
Aamir Hussain
Leqembi for Grand father
Invimeds helped me for providing my grand father LEQEMBI for Alzheimers in far flung area of Uttarkhand.
Shivam Pandit
Thankyou Invimeds
Thank you Invimeds team for providing Zejula for my grand mother at earliest. This has helped us a lot to go ahead with her cancer treatment.
Satrudhan Shukla

Word Wide Delivery:

India, Andorra, Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe, Afghanistan, Albania, Algeria, American Samoa, Angola, Anguilla, Antarctica, etc.

×